Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 3(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01693328Unknown

Patient Satisfaction and Quality of Life Impact - PecFent®

Role: lead

NCT00458510Phase 3Completed

Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain

Role: lead

NCT01698645Unknown

Patient Satisfaction and Quality of Life Impact - PecFent®

Role: lead

NCT00459277Phase 3Completed

Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Role: lead

NCT00589823Phase 3Completed

Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Role: lead

NCT00767221Phase 2Completed

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

Role: collaborator

All 6 trials loaded